,28,29 Treatment alternatives for cases of leukemia with CDKN2A mutations encompass the targeting of the CDK2-SKP2 axis, the utilization of the small-molecule CDK4/6 inhibitor known as palbociclib, and the application of the innovative CDK2/9 inhibitor referred to as fadraciclib.30 Here, CDK2 is linked to leukemia.